Alexandre Tungesvik
Overview
Explore the profile of Alexandre Tungesvik including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
5
Citations
27
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sudalagunta P, Canevarolo R, Meads M, Silva M, Zhao X, Cubitt C, et al.
Cancer Res
. 2024 Oct;
85(2):378-398.
PMID: 39476082
Several therapeutic agents have been approved for treating multiple myeloma, a cancer of bone marrow-resident plasma cells. Predictive biomarkers for drug response could help guide clinical strategies to optimize outcomes....
2.
Jiang Q, Sudalagunta P, Silva M, Canevarolo R, Zhao X, Ahmed K, et al.
Bioinformatics
. 2022 Jun;
38(16):4002-4010.
PMID: 35751591
Motivation: Time-lapse microscopy is a powerful technique that relies on images of live cells cultured ex vivo that are captured at regular intervals of time to describe and quantify their...
3.
Mostofa A, Distler A, Meads M, Sahakian E, Powers J, Achille A, et al.
JCI Insight
. 2021 Nov;
6(24).
PMID: 34793338
The clinical utility of histone/protein deacetylase (HDAC) inhibitors in combinatorial regimens with proteasome inhibitors for patients with relapsed and refractory multiple myeloma (MM) is often limited by excessive toxicity due...
4.
Koomen D, Meads M, Magaletti D, Guingab-Cagmat J, Oliveira P, Fang B, et al.
J Proteome Res
. 2021 May;
20(6):3134-3149.
PMID: 34014671
Multiple myeloma is an incurable hematological malignancy that impacts tens of thousands of people every year in the United States. Treatment for eligible patients involves induction, consolidation with stem cell...
5.
Sudalagunta P, Silva M, Canevarolo R, Alugubelli R, DeAvila G, Tungesvik A, et al.
EBioMedicine
. 2020 Apr;
54:102716.
PMID: 32268267
Background: Multiagent therapies, due to their ability to delay or overcome resistance, are a hallmark of treatment in multiple myeloma (MM). The growing number of therapeutic options in MM requires...